Printer Friendly
The Free Library
14,503,364 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

ONCOLYTICS ENROLLED FOR PHASE I SYSTEMIC DELIVERY OF REOLYSIN.


Oncolytics Biotech Inc. (TSX:ONC, NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
:ONCY), Calgary, it has completed patient enrolment in its Phase I U.S. clinical trial investigating the systemic delivery of REOLYSIN(R) to treat patients with advanced cancers. A total of 18 patients were treated in the Phase I trial with REOLYSIN(R) at escalating dosages of 1x10(8), 3x10(8), 1x10(9), 3x10(9), 1x10(10) or 3x10(10) TCID TCID

tissue culture infective dose; that amount of a pathogenic agent that will produce pathological change when inoculated on tissue cultures.
(50). A maximum tolerated dose (MTD) was not reached and the treatment appears to have been well tolerated by the patients.

The clinical trial is an open-label, dose-escalation Phase I study in which a single dose of REOLYSIN(R) was administered intravenously to patients diagnosed with selected advanced or metastatic solid tumours that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists. The primary objective of the study is to determine the MTD, dose limiting toxicity and safety profile of REOLYSIN(R). Secondary objectives include the evaluation of viral replication, immune response to the virus and any evidence of anti-tumour activity.

The principal investigator for the trial is Dr. Sanjay Goel, Assistant Professor and Attending Physician in the Department of Medical Oncology, Montefiore Medical Center Montefiore Medical Center, in the Bronx, New York, is the university hospital of the Albert Einstein College of Medicine. The hospital, named after Moses Montefiore, is one of the 50 largest employers in New York State [1].  and Albert Einstein College of Medicine
For the engineering company, see AECOM


The Albert Einstein College of Medicine (AECOM) is a graduate school of Yeshiva University. It is a private medical school located in the Jack and Pearl Resnick Campus of Yeshiva University in the Morris Park
, New York City New York City: see New York, city.
New York City

City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S.
.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase I/II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus reovirus

Any of a small group of animal and plant viruses that appear spheroidal and contain a core of RNA. Among the best-known genera are Orthoreovirus, Orbivirus, Rotavirus, and Phytoreovirus. The first three infect animals; the last can destroy rice, corn, and other crops.
, alone and in combination with radiation.

For more information, visit www.oncolyticsbiotech.com or call 403/670-7377.
COPYRIGHT 2006 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Biotech
Geographic Code:1CANA
Date:Oct 1, 2006
Words:271
Previous Article:ULTASOUND RADIOFREQUENCY USED TO TREAT HEPATIC CYSTS.
Next Article:ASTELLAS' SCREENING TRIGGERS MILESTONE PAYMENT TO METABOLEX.
Topics:



Related Articles
ENCOURAGING RESULTS FROM RHEUMATOID ARTHRITIS STUDY.
PHASE IIB MBI 594AN STUDY VALIDATES ANTI-ACNE PROPERTIES.
Seattle Genetics Provides Update on SGN-30 and SGN-40 Clinical Programs at ASCO.
Seattle Genetics Reports on SGN-30 Clinical Program at the American Society of Hematology Annual Meeting.
ONCOLYTICS ISSUED U.S. PATENT FOR PRODUCING REOVIRUS.
Zelos and Nektar Announce Start of Phase 1 Trial of Inhaled Ostabolin-C(TM) for Osteoporosis.
ZELOS/NEKTAR START PHASE 1 TRIAL OF INHALED OSTABOLIN-C.
APPROVAL FOR U.K. CLINICAL TRIAL FOR REOLYSIN.
Lux Biosciences Initiates Clinical Trials of Its Second Pivotal Stage Program.
Nucleonics Receives FDA Clearance to Begin Phase 1 Trial of Expressed RNAi Approach to Treating Chronic Hepatitis B Infections.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles